Feb 2022 $2 M No. 4 Under $2 million 1
Titan Pharmaceuticals Inc.: Raise no. 4, Feb 2022 × Investors in this round 1 investor had bought by the notice of Feb 7, 2022: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Titan Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $7 M offered; $6 M still to sell
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $106,447
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Katherine Beebe DeVarney · Executive Officer, Director Marc Rubin · Executive Officer, Director · Executive Chairman James R. McNab, Jr. · Director Joseph A. Akers · Director M. David McFarlane · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · New York, New York Sold in NY Remarks in the notice On the amounts: “Offering amount represents 1,289,796 Pre-Funded Warrants and 4,664,038 Placement Warrants at a combined purchase price of $1.179 per warrant. Amount sold represents 1,289,796 Pre-Funded warrants.”Signed by Kate Beebe DeVarney, Ph.D., President and COO. Source: SEC Form D, newest notice filed Feb 7, 2022. Read the notice at the SEC .
options SEC Jan 2021 $10 M No. 3 $2 to $10 million 7
Titan Pharmaceuticals Inc.: Raise no. 3, Jan 2021 × Investors in this round 7 investors had bought by the notice of Jan 21, 2021: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Titan Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $677,162
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Katherine Beebe DeVarney · Executive Officer, Director Marc Rubin · Executive Officer James R. McNab, Jr. · Director Joseph A. Akers · Director M. David McFarlane · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kate Beebe DeVarney, Ph.D., President and COO. Source: SEC Form D, newest notice filed Jan 21, 2021. Read the notice at the SEC .
options SEC Jan 2020 $2 M No. 2 $2 to $10 million 5
Titan Pharmaceuticals Inc.: Raise no. 2, Jan 2020 × Investors in this round 5 investors had bought by the notice of Jan 9, 2020: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Titan Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $152,250
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dane Hallberg · Executive Officer Katherine DeVarney · Executive Officer, Director Marc Rubin · Executive Officer, Director Sunil Bhonsle · Executive Officer, Director James R. McNab, Jr. · Director Joseph A. Akers · Director M. David McFarlane · Director Scott A. Smith · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On fees: “Represents a 7% fee paid pursuant to a placement agency agreement.”On the amounts: “Represents private placement warrants to purchase up to 8,700,000 shares of common stock issued in connection with a concurrent registered direct offering. Total Offering Amount includes the securities sold in such concurrent registered direct offering.”Signed by Sunil Bhonsle, CEO and President. Source: SEC Form D, newest notice filed Jan 9, 2020. Read the notice at the SEC .
options SEC Aug 2019 $2 M No. 1 $2 to $10 million 1
Titan Pharmaceuticals Inc.: Raise no. 1, Aug 2019 × Investors in this round 1 investor had bought by the notice of Aug 19, 2019: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Titan Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $148,786
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dane Hallberg · Executive Officer Katherine Beebe · Executive Officer Marc Rubin · Executive Officer, Director Sunil Bhonsle · Executive Officer, Director James R. McNab, Jr. · Director Joseph A. Akers · Director M. David McFarlane · Director Rajinder A. Kumar · Director Scott A. Smith · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On fees: “Represents a 7% fee paid pursuant to a placement agency agreement.”On the amounts: “Represents private placement warrants to purchase up to 2,852,314 shares of common stock issued in connection with a concurrent registered direct offering. Total Offering Amount includes the securities sold in such concurrent registered direct offering.”Signed by Sunil Bhonsle, CEO and President. Source: SEC Form D, newest notice filed Aug 19, 2019. Read the notice at the SEC .
options SEC